FDA To Send Draft Ranexa Label Shortly
This article was originally published in The Pink Sheet Daily
Executive Summary
CV Therapeutics CEO is bullish on clearance in first-line angina.
You may also be interested in...
Sales Reps Will Make Case For Ranexa In First-Line Angina
New label, which exceeded CV Therapeutics’ expectations, highlights reduction of hemoglobin A1c levels and arrhythmias.
Sales Reps Will Make Case For Ranexa In First-Line Angina
New label, which exceeded CV Therapeutics’ expectations, highlights reduction of hemoglobin A1c levels and arrhythmias.
CV Therapeutics Inks Ex-U.S. Ranexa Deal
With Menarini, angina drug will launch in the U.K. and Germany early next year.